Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Xometry Q1 2026 Earnings Call - Record Growth and Strategic Siemens Partnership Drive Acceleration
Xometry reported record Q1 2026 results with revenue accelerating 36% year-over-year to $205 million, driven by a 40% surge in marketplace sales and expanding margins. The company raised its full-year...
- Revenue grew 36% year-over-year to $205 million, with a 600 basis point acceleration from Q4, marking three consecutive quarters of accelerating growth.
- Marketplace revenue surged 40% year-over-year, outpacing overall growth and driven by strong enterprise adoption and expanding wallet share.
- Active buyers increased 20% year-over-year to 85,581, with net additions of 3,760, the highest in nine quarters, reflecting successful product-led growth strategies.
- +9 more takeaways
Bob's Discount Furniture Q1 2026 Earnings Call - Resilient Growth Amidst Macro Headwinds
Bob's Discount Furniture delivered an 8.5% year-over-year sales increase in Q1 2026, driven by new store expansion and a 1.2% comparable sales growth, despite adverse winter weather and a challenging ...
- Total net sales increased 8.5% year-over-year to $578.1 million, driven by new store openings and 1.2% comparable store sales growth.
- Adjusted EBITDA margin came in at 6.5%, slightly ahead of management expectations, despite extreme weather disruptions.
- Customers are trading up from the 'good' to 'better' price tiers, with broad-based strength across motion, bedroom, and mattress categories.
- +7 more takeaways
Lesaka Technologies Q3 FY2026 Earnings Call - Consumer Division Drives Record Profitability While Merchant Transformation Nears Completion
Lesaka Technologies delivered a record-breaking Q3 FY2026, with group adjusted EBITDA surging 45% year-over-year to ZAR 337 million and adjusted earnings jumping 246% to ZAR 148 million. The Consumer ...
- Group adjusted EBITDA rose 45% to ZAR 337 million, marking an all-time quarterly high and hitting the top end of guidance.
- Adjusted earnings surged 246% to ZAR 148 million, with adjusted EPS jumping from ZAR 0.52 to ZAR 1.80.
- Consumer division EBITDA grew 81% to a record ZAR 213 million, fueled by a 33% year-over-year increase in lending originations to ZAR 856 million.
- +7 more takeaways
Lincoln Financial Group Q1 2026 Earnings Call - Seventh Consecutive Quarter of Adjusted Operating Income Growth Driven by Strategic Shift to Spread-Based Products
Lincoln Financial Group delivered another quarter of disciplined execution, posting a 16% year-over-year increase in adjusted operating income for the seventh consecutive quarter. The results undersco...
- Adjusted operating income grew 16% year-over-year, marking the seventh consecutive quarter of growth and signaling strong execution of the company's strategic priorities.
- Fixed indexed annuity (FIA) sales surged over 90% year-over-year, reflecting a successful pivot away from price-sensitive MYGA products toward differentiated, spread-based offerings.
- Group Protection operating income rose 11% year-over-year, with margin expanding 60 basis points to 8%, driven by favorable Group Life underwriting and disciplined pricing.
- +7 more takeaways
EPR Properties Q1 2026 Earnings Call - Accelerating Investment and Upside Guidance on Experiential Resilience
EPR Properties delivered a 5.9% year-over-year increase in FFO as adjusted per share in Q1 2026, driven by strong experiential spending and the strategic acquisition of a 7-park Six Flags portfolio. T...
- FFO as adjusted per share grew 5.9% year-over-year to $1.26, with AFFO per share rising 6.6% to $1.29.
- Full-year 2026 FFO guidance increased to $5.37-$5.53 per share, representing 6.5% growth at the midpoint.
- Investment spending guidance raised to $500 million-$600 million, the highest level since the pandemic.
- +7 more takeaways
Iovance Biotherapeutics Q1 2026 Earnings Call - AMTAGVI Demand Surges as Iovance Pivots to In-House Manufacturing and Pipeline Expansion
Iovance Biotherapeutics delivered a strong first quarter of 2026, with revenue growing 45% year-over-year to $71 million, driven by robust AMTAGVI demand and strategic cost discipline. The company suc...
- Q1 2026 revenue reached $71 million, a 45% year-over-year increase, fueled by $60 million in AMTAGVI sales and $11 million in Proleukin revenue.
- AMTAGVI production is now exclusively in-house at Iovance’s internal facility, ICTC, following a temporary capacity reduction for maintenance upgrades, with management confident in uninterrupted supply.
- Second-quarter revenue guidance is raised to $86 million-$88 million, with AMTAGVI revenue expected to hit $79 million-$81 million, marking a 23% increase over the previous record quarter.
- +12 more takeaways
NCR Voyix Q1 2026 Earnings Call - Software & Services Momentum Offsets Hardware Transition, VCP Pipeline Surges
NCR Voyix delivered a solid first quarter, with total revenue nearly flat at $606 million and adjusted EBITDA rising 5% to $78 million. The growth was driven by cost discipline and accelerating adopti...
- Total revenue decreased 1% year-over-year to $606 million, while adjusted EBITDA increased 5% to $78 million, driven by cost actions and software revenue growth.
- Recurring software and services revenue both increased 4%, signaling a successful transition toward a software-led business model.
- The company signed 21 new Voyix Commerce Platform (VCP) contracts, representing $293 million in remaining contract value, up 75% year-over-year.
- +7 more takeaways
Stratasys Q1 2026 Earnings Call - Defense Demand and Dental Certification Drive Strategic Pivot
Stratasys reported a measured first quarter in 2026, with revenue declining 2.4% year-over-year to $132.7 million as customers exercised capital discipline amid global uncertainty. However, the compan...
- Revenue declined 2.4% year-over-year to $132.7 million, reflecting customer capital discipline in a measured spending environment.
- Stratasys Direct delivered 23% organic growth, driven by production-scale additive manufacturing for defense and aerospace customers.
- The company secured a multi-million dollar contract for the Department of Defense’s JAMA IV pilot program, accelerating qualification of 3D-printed parts for military platforms.
- +7 more takeaways
Scholar Rock Q1 2026 Earnings Call - FDA Accepts Apitegromab BLA for SMA with Dual Manufacturing Paths to PDUFA
Scholar Rock’s Q1 2026 earnings call centered on a single, high-stakes milestone: the FDA’s acceptance of its Biologics License Application for apitegromab, the world’s first muscle-targeted therapy f...
- FDA Accepts Apitegromab BLA: The FDA accepted Scholar Rock’s BLA for apitegromab for SMA, assigning a PDUFA date of September 30, 2026. Approval could be granted at any time prior to that date.
- Dual Manufacturing Paths: The BLA includes two U.S. fill-finish facilities—Catalent, Indiana (subject to FDA reclassification) and a second independent site. All drug product for FDA review at the second site has been filed.
- Catalent Reinspection Complete: The FDA completed an unannounced reinspection of the Catalent, Indiana facility in early Q2. The agency now has up to 90 days to classify the site’s status.
- +9 more takeaways
Liberty Latin America Q1 2026 Earnings Call - Preferred Dividend Signals Confidence Amid Hurricane Recovery
Liberty Latin America delivered a Q1 2026 adjusted OIBDA of $405 million, beating internal targets despite a full quarter of headwinds from Hurricane Melissa and phasing in its Liberty Networks segmen...
- Adjusted OIBDA of $405 million in Q1 2026 exceeded internal expectations, driven by strong performance in Jamaica and Liberty Caribbean despite Hurricane Melissa headwinds.
- Adjusted free cash flow before distributions improved by $40 million year-over-year to negative $64 million, reflecting lower capital expenditures and stronger operating cash flow.
- Liberty Latin America announced a $500 million notional 9% cash-pay preferred equity dividend, signaling confidence in future free cash flow and aiming to regear the common equity structure.
- +7 more takeaways